



GOG PARTNERS CONNECTION

A Quarterly Newsletter

From GOG Partners, A GOG Foundation Program

The GOG Foundation, Inc. has one mission that is dedicated to transforming the standard of care in gynecologic oncology.

WISHING YOU A HAPPY HOLIDAY SEASON FROM THE GOG FOUNDATION, INC. (GOG-F)

Dear Colleagues,

As we take a moment to celebrate the holiday season and the arrival of a New Year with our friends, family and loved ones, let us also take a moment to recognize our successes in 2023.

I am awed by your dedication to our mission, helping to find better treatment strategies for our patients, which is reflected in the accomplishments we have achieved. Thank you, GOG-F Sites, for your efforts, commitment, and contributions from our incredible teams, institutions, and practices. I am humbled to work with an amazing team of physician leaders, and an incredible staff that make the magic happen on a daily basis.



In the coming year, we will continue our focus on transforming the standard of care for all patients with gynecologic cancer. It is our goal to ensure that our clinical trial enrollment reflects our disease-state populations by proportionately including racial and ethnic minorities in our trials. It is our collective passion to expediently enroll existing GOG-F trials and develop novel studies in the upcoming year. We have the privilege to work in health care, and the health and wellbeing of ourselves and our community are important priorities that can suffer with everyone working days, nights, weekends, and holidays. Thus, I want to extend a heartfelt thank you to all of you for your tireless efforts on behalf of our patients.

But with these continuous demands, it is important to disconnect and take time to reenergize, relax, and recharge. Self-care is easy to neglect as we devote our energies to serving others—patients, colleagues, friends, and families—but it is key to our physical and mental health. Please make yourself a priority during this holiday season.

I hope that you share my immense gratitude for the opportunity that we have to work, laugh, empathize, and support one another. Together, we will start 2024 stronger than ever.

Together, our strength will continue to positively impact patients through the prevention and treatment of gynecologic cancers. On behalf of the GOG-F, I wish you a safe and healthy holiday season and a most prosperous New Year.

Happiest of holidays to each of you!

With warmest regards,
Tom

GOG PARTNERS INVESTIGATOR INITIATED TRIAL APPLICATION NOW OPEN

In support of our dedication to transforming the standard of care in gynecologic oncology, the GOG Foundation, Inc. Investigator Initiated Trial (IIT) program supports studies with scientific merit that are independent of academic, government or industry sponsored trials. These trials are designed to have a direct impact on patients by assessing available treatments and generating data applicable to the local population at both academic and community-based sites through the GOG Partners Program. GOG physician leadership provides mentorship for the next generation of investigators leading these IITs.

GOG is currently accepting new IIT Letter of Intent (LOI) applications until **January 18, 2024**. Applications should be submitted electronically using the IIT LOI form on the GOG website.

All applications will be reviewed jointly by the GOG Partners IIT Committee based on:

- Scientific Relevance
- Practice-Changing Potential
- Study Design
- Study Feasibility
- Use of Standard of Care Assessments

Proposed studies must be IND Exempt to be considered by GOG. Applicants must be on staff of a GOG network site in good standing.

Please contact GOGPartners@gog.org with any questions.

[Apply Now](#)

SPECIAL RECOGNITION

Premal Thaker, MD named the inaugural David & Lynn Mutch Distinguished Professor of Obstetrics

Premal H. Thaker, MD, MS, an accomplished clinician investigator and Director of Gynecologic Oncology Clinical Trials, has been named the David & Lynn Mutch Distinguished Professor of Obstetrics and Gynecology at Washington University School of Medicine in St. Louis.



“We are truly fortunate to have Dr. Thaker as a valued member of our faculty. Her outstanding contributions to patient care, clinical and translational research, and training the next generation of students, residents and fellows, make her the ideal recipient of this tremendous honor,” said Dineo Khabele, MD, Chair of the Department of OB/GYN.

“Since I was recruited by Dr. Mutch after completing my fellowship at M. D. Anderson Cancer Center, I am very humbled, honored, and delighted to be the inaugural David G. and Lynn Mutch Distinguished Professor of Obstetrics and Gynecology,” Dr. Thaker stated. “I would like to thank the Berges Family Foundation for their support in honoring Dr. Mutch who is the epitome of the tripartite mission: research, education, and patient care. I am privileged that I have been selected to continue his legacy and vision to strengthen our ability to advance new treatments with clinical trials, to educate the next generation of leaders, and to treat gynecologic oncology patients with compassion and grace”. Premal Thaker, MD

[Click here](#) to read the full article.

AVAILABLE TODAY

This publication is dedicated to Larry J. Copeland, MD for his incredible leadership in serving as The GOG Foundation, Inc. President from 2017 - 2023



[Click Here](#)

IN THE NEWS

THE LANCET GOG-3030 (BEATcc) PUBLICATION

Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial

THE
LANCET

The GOG-0240 trial established bevacizumab with chemotherapy as standard first-line therapy for metastatic or recurrent cervical cancer. In the BEATcc trial (ENGOT-Cx10-GEICO 68-C-JGOG1084-GOG-3030), we aimed to evaluate the addition of an immune checkpoint inhibitor to this standard backbone.

[Click here](#) to read the full publication.

THE NEW ENGLAND JOURNAL OF MEDICINE GOG-3045 (MIRASOL) PUBLICATION



The NEW ENGLAND
JOURNAL of MEDICINE

Mirvetuximab Soravtansine in FR α -Positive, Platinum-Resistant Ovarian Cancer

Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FR α), is approved for the treatment of platinum-resistant ovarian cancer in the United States.

[Click here](#) to read the full publication.

THE WHITE HOUSE FACT SHEET



President Joe Biden to Announce First-Ever White House Initiative on Women’s Health Research, An Effort Led by First Lady Jill Biden and the White House Gender Policy Council

The new initiative will fundamentally change how we approach and fund women’s health research.

Despite making up more than half of the population, women have been understudied and underrepresented in health research for far too long. Research on women’s health is drastically underfunded, leading to significant research gaps, with serious consequences for the health of women across the country. This lack of investment limits our understanding of conditions that are specific to women, predominantly affect women, or affect women differently. In order to give women and their health care providers the tools and information that they need to more effectively prevent, diagnose, and treat these conditions – from rheumatoid arthritis to menopause to Alzheimer’s disease to cardiovascular disease to endometriosis – our nation must fundamentally change how we approach and fund women’s health research.

[Click here](#) to read the full announcement.

GYNECOLOGIC ONCOLOGY GOG-3032 (MOONSTONE) PUBLICATION



Niraparib and dostarlimab for the treatment of recurrent platinum-resistant ovarian cancer: results of a Phase II study

This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase inhibitor, in patients with BRCA wild type (BRCAwt) recurrent platinum-resistant ovarian cancer (PROC) who had previously received bevacizumab treatment.

[Click here](#) to read the full publication.

FOX NEWS CHANNEL innovaTV301 | ENGOT-cx12 GOG-3057 ARTICLE



A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator’s Choice Chemotherapy in Second - or Third-Line recurrent or Metastatic Cervical Cancer

"To have an overall survival advantage in this disease is extremely, extremely rare. It changes the second-line standard of care for this disease. Now, all patients who recur after first-line therapy should be considered for this therapy. So it's a game-changer." Brian Slomovitz, MD

[Click here](#) to read the full article.

JOURNAL OF CLINICAL ONCOLOGY ENGOT-cx8 | GOG-3024 innovaTV205 PUBLICATION

**Journal of
Clinical
Oncology®**

Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

Tissue factor is highly expressed in cervical carcinoma and can be targeted by tisotumab vedotin (TV), an antibody-drug conjugate. This phase Ib/II study evaluated TV in combination with bevacizumab, pembrolizumab, or carboplatin for recurrent or metastatic cervical cancer (r/mCC).

[Click here](#) to read full publication.

**LOW-GRADE SEROUS OVARIAN CANCER:
EXPERT CONSENSUS REPORT ON
THE STATE OF THE SCIENCE VIDEO PODCAST**

Brian Slomovitz, MD
Mount Sinai Medical Center

Rachel Grisham, MD
Memorial Sloan Kettering Cancer Center

David Gershenson, MD
UT M.D. Anderson Cancer Center

The GOG Foundation, Inc. would like to thank Verastem Oncology for their support of this video podcast.

[Click here](#) to view the full video podcast.

To learn more about low-grade serous ovarian cancer, [click here](#) to view the panel's Low-grade serous ovarian cancer: expert consensus report on the state of the science paper published in the International Journal of Gynecologic Cancer.

CLINICAL TRIALS

The GOG Partners Program is currently recruiting for 22 clinical trials

- **15 Ovary**

- 1 Cervix
- 6 Endometrium

To search active trials visit our website by clicking Clinical Trials button below.



Clinical Trials

FEATURED CLINICAL TRIALS

GOG-3031 (RUBY) PRESS RELEASE



Jemperli (dostarlimab-gxly) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer

December 2, 2023 – GSK plc (LSE/NYSE: GSK) today announced positive headline results from the planned interim analysis of Part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase III trial investigating Jemperli (dostarlimab-gxly) plus standard-of-care chemotherapy (carboplatin-paclitaxel) followed by Jemperli compared to chemotherapy plus placebo followed by placebo in adult patients with primary advanced or recurrent endometrial cancer. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS). It showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.

While the overall survival (OS) data were immature at the time of this analysis, a favorable trend was observed in the overall population, including both the dMMR/MSI-H and MMRp/MSS subgroups.

The safety and tolerability profile of dostarlimab-gxly in the RUBY phase III trial was consistent with clinical trials of similar regimens. The most common treatment-emergent adverse events in patients receiving dostarlimab-gxly plus chemotherapy were nausea, alopecia, fatigue, peripheral neuropathy, anemia, arthralgia, constipation and diarrhea.

[Click here](#) to view the full press release.

GOG-3020 (ATHENA) PRESS RELEASE



European Commission Approves pharmaand GmbH's Rubraca® (rucaparib) as a First-Line Maintenance Treatment in Advanced Ovarian Cancer

Vienna, Austria, November 20, 2023 – pharmaand GmbH (pharma&) announced today that the European Commission (EC) has granted marketing authorization for a Type II variation for Rubraca® (rucaparib) as a first-line maintenance treatment for all women with advanced ovarian cancer regardless of their BRCA mutation status, who have responded to first-line platinum-based chemotherapy.

Rucaparib was previously approved as a monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to platinum-based chemotherapy.

[Click here](#) to view the full press release.

innovaTV 301 | ENGOT cx12 | GOG-3057
PRESS RELEASE



TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial

October 22, 2023: Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced results today from the Phase 3 innovaTV 301 randomized global trial, which showed treatment with TIVDAK demonstrated a statistically significant and clinically meaningful 30% reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after first-line therapy, compared with chemotherapy (HR: 0.70, 95% CI: 0.54-0.89, p=0.00381). Data were presented during the Presidential Symposium at the European Society of Medical Oncology (ESMO) Congress 2023.

“Patients with cervical cancer have few treatment options once their cancer comes back or spreads after initial treatment,” said Ignace B. Vergote, M.D., Ph.D., co-founder of European Network of Gynaecological Oncological Trial groups (ENGOT), and lead investigator on the innovaTV 301/ENGOT cx-12/GOG 3057 clinical trial. “The positive data, seen in a representative patient population of recurrent or metastatic cervical cancer, demonstrate the potential for TIVDAK to reshape clinical practice and provide hope for patients who need a new treatment option.”

[Click here](#) to view the full press release.

GOG-3041 (DUO-E) | ENGOT-EN10 PRESS
RELEASE



Imfinzi plus Lynparza reduced the risk of disease progression or death by 45% vs. chemotherapy in advanced or recurrent endometrial cancer

October 21, 2023: Positive results from the primary analysis of the DUO-E Phase III trial showed that *Imfinzi* (durvalumab) plus platinum-based chemotherapy, followed by either *Imfinzi* monotherapy or *Imfinzi* plus *Lynparza* (olaparib), both demonstrated a statistically significant

and clinically meaningful improvement in progression-free survival (PFS) compared to chemotherapy alone in the overall trial population of patients with newly diagnosed advanced or recurrent endometrial cancer.

Shannon N. Westin, Professor of Gynecologic Oncology and Reproductive Medicine at The University of Texas MD Anderson Cancer Center, and principal investigator of the trial, said, “These findings showcase, for the first time, the potential of combining immunotherapy with a PARP inhibitor to deliver significant clinical improvements for these patients. These DUO-E data may offer oncologists novel avenues to enhance outcomes for endometrial cancer patients.”

[Click here](#) to view the full press release.

ENGOT-cx11| GOG-3047 (KEYNOTE A18) PRESS RELEASE



FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

September 20, 2023: Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy (EBRT) plus concurrent chemotherapy, followed by brachytherapy (also known as concurrent chemoradiotherapy) as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer. The sBLA is based on data from the KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, in which KEYTRUDA plus concurrent chemoradiotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to concurrent chemoradiotherapy alone. If approved, this would be Merck’s third approved indication in cervical cancer and first in an earlier stage of the disease. The FDA has set a Prescription Drug User Fee Act (PDUFA), or target action, date of January 20, 2024.

“The standard of care for patients with locally advanced cervical cancer has not changed in more than two decades, and the majority of patients will experience recurrence or progression of their disease,” said Dr. Gursel Aktan, vice president, global clinical development, Merck Research Laboratories. “If approved, KEYTRUDA will be the first immunotherapy available for patients with newly diagnosed high-risk locally advanced cervical cancer. We are committed to working closely with the FDA to bring KEYTRUDA to these patients who are in need of additional treatment options.”

[Click here](#) to view the full press release.

ENGOT-ov60 | GOG-3052 | RAMP 201 VIDEO PODCAST

Overview of The Planned Interim Analysis Presented at ASCO 2023

A Phase 2 study of VS-6766 (RAF/MEK clamp) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer



Kathleen Moore, MD
Stephenson Cancer Center



Bradley J. Monk, MD
University of Arizona College of Medicine
Creighton University School of Medicine



Susana Banerjee, MBBS, MA, PhD, FRCP
The Royal Marsden and
the Institute of Cancer Research



[Click here](#) to view the full video podcast and learn more about this clinical trial in recurrent low-grade serous ovarian cancer.

UPCOMING INDUSTRY MEETINGS

NRG 2024 WINTER MEETING

The NRG 2024 Winter Meeting will be held **February 15 - 17, 2024 in Orlando, Florida** at the World Center Marriott



[Click here](#) to visit the NRG 2024 Winter Meeting resource pages that will provide up-to-date registration and hotel information, agendas, and session recordings. Please visit the Help page if you have unanswered questions or need support.

SGO 2024 WINTER MEETING

The SGO Winter Meeting will be held **January 25 - 27, 2024** at the Everline Resort & Spa in **Olympic Valley, California**.



Gynecologic oncologists, radiation oncologists, medical oncologists, obstetricians and gynecologists, and allied health professionals involved in the care of patients who have gynecologic cancers are encouraged to attend the SGO Winter Meeting.

[Click here](#) to register to attend.

ESGO 2024 CONGRESS

The ESGO 2024 Congress will be held **March 7 - 10, 2024 in Barcelona, Spain**



ESGO 2024 will be a celebration of discovery and late-breaking research, new guidelines, practical demonstrations, and

exclusive live surgery transmissions from hospitals you don't want to miss.

The 25th Congress of the European Society of Gynaecological Oncology will bring together over 2,000 attendees from around the world for a four-day gathering of learning, networking, and sharing the latest developments in the field of Gynaecological Cancers—all with the goal of enhancing your knowledge, accelerating your skills and advancing the field.

[Click here](#) for more information.

2024 SGO ANNUAL MEETING ON WOMEN'S CANCER

The 2024 SGO Annual Meeting on Women's Cancer will be held **March 16 - 18, 2024 in San Diego, California.**

Since 1969, gynecologic oncology professionals have convened at the Society of Gynecologic Oncology (SGO)'s Annual Meeting on Women's Cancer to discuss the latest science in the field, receive educational programming, and to network.

Members of the entire gynecologic cancer care team who provide treatment and care in the areas of chemotherapy, radiation therapy, surgery, and palliative care attend the SGO Annual Meeting. Gynecologic oncologists make up a large population of the attendees, along with medical oncologists, pathologists, radiation oncologists, hematologists, surgical oncologists, obstetrician/gynecologists, nurses, physician assistants, fellows in training, residents, and pharmacists.

[Click here](#) for more information.



ON DEMAND EDUCATION

OVARIAN CANCER ONLINE SYMPOSIUM

Join this three-part, online symposium for impactful ovarian cancer information, education and support. The sessions are personalized for patients, caregivers and other advocates and offered at no cost to participants.

- Symposium Intro & Ovarian Cancer Overview
- Platinum-Sensitive and Platinum-Resistant Recurrence
- Understanding Clinical Trials and The OC Roadmap

[Click here](#) to register to access the Ovarian Cancer Online Symposium video recordings.



The Clarity Foundation and GOG Partners are grateful for our commercial supporters for Independent Medical Education associated with this podcast series: *Novocure, Verastem, Immunogen, Alkermes, R-Pharm US, GSK.*

THE GOG HIGHLIGHT REEL - FALL 2023



Access to Symposium Recording

Please [click here](#) to register for access to view the recording of this symposium. Once you have completed the registration, a confirmation email will be sent to the email you provide with access to the GOG Highlight Reel – Fall 2023 recording.

Access to Symposium Presentations

Please [click here](#) to access the individual presentation files on the GOG website.

2023 IGCS ANNUAL GLOBAL MEETING



You may access IGCS 2023 On-Demand by logging into [IGCS Education360 Learning Portal](#) with your IGCS account login information, which is same information you used to register for the meeting.

On-Demand is available until February 5, 2024.

If you are unsure of your IGCS account login information, please contact igcs@igcs.org.

Once you are logged into Education360 Learning Portal, select “My Courses” on the left panel.

From the list of your courses find “IGCS 2023 Annual Global Meeting - On-Demand”.

Within this course, you will find recordings, abstracts, ePosters, and surgical films.

Don't miss out on the following Industry Supported Symposia that were presented at the 2023 IGCS Annual Global Meeting!

IGCS 2023

GOG FOUNDATION
Transforming the standard of care™

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting

**Target Practice:
Zeroing in and Eliminating Ovarian Cancer. A course to review and understand the ADC opportunities that exist in Ovarian Cancer**

This session is not included in main Congress CEMCPD credit

12:40 - 12:45: Kathleen Moore, MD
Welcome & Introductions

12:45 - 13:05: Isabelle Ray-Coupard, MD, PhD
ADC Opportunities in Ovarian Cancer

13:05 - 13:35: Linda Duska, MD
Patient Focused Treatment QOL with ADCs: The ABCs for Patient Care

13:35 - 13:35: All Faculty
Panel Discussion: Available Treatments and Most Active Target/Payload Combination

13:35 - 13:55: Báilín O'Carroll, MD
Important Advancements in Clinical Trial Development: How Lessons Learned Influence and Shape Future Opportunities

13:55 - 14:10: All Faculty
Panel Discussion and Audience Q&A

Kathleen Moore, MD
Linda Duska, MD
Báilín O'Carroll, MD
Isabelle Ray-Coupard, MD, PhD

The GOG Foundation, Inc. is grateful for our commercial supporters for this symposium: Immunogen, Mersana, and Novocure

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting

AN EVOLVING FRONTIER - UNDERSTANDING NOVEL TREATMENT OPTIONS FOR THE MANAGEMENT OF ADVANCED STAGE OR RECURRENT ENDOMETRIAL CANCERS



This session is not included in the main event CME/CPD credit.

12:40 - 12:45: Ramez Eskander, MD
Welcome & Introductions

12:45 - 13:10: Ramez Eskander, MD
The Evolving Treatment Landscape for The Management of Endometrial Cancer

13:10 - 13:35: Stephanie Lheureux, MD, PhD
Immunotherapy After Immunotherapy, What Are The Opportunities for Immune Check-Point Inhibition Re-challenge and The Role of Pembrolizumab/Lenvatinib

13:35 - 14:00: Anna Fagotti, MD, PhD
Disparities in Endometrial Cancer Outcomes, What More Can We Do?

14:00 - 14:10: All Faculty
Discussion & Wrap Up



Ramez Eskander, MD
US Oncology Network
Comprehensive Cancer Center



Anna Fagotti, MD, PhD
Fondazione Policlinica Universitario
"Paolo Corelli" IRCCS, Università
Cagliari and Sanofi-Genzyme



Stephanie Lheureux, MD, PhD
Princess Margaret Cancer Centre



JOIN US TODAY >

Sunday, November 5, 2023
12:40 - 14:10 KST

COEX, Grand Ballroom 101-102

International Gynecologic Cancer Society 2023 Annual Global Meeting

The 3 Es of ICI in endometrial cancer: emergence, evolution, and expansion

Monday, November 6, 2023 | 12:40 - 14:10 KST
COEX Convention Center | Room: Grand Ballroom 103 | Seoul, Republic of Korea

CHAIR



Dr. Byoung-Gie Kim



Dr. Jung-Yun Lee




Dr. Mansoor Raza Mirza



Dr. David SP Tan

- Foundations of the EC management landscape
Dr. Byoung-Gie Kim (Chair)
- Emergence of ICI: monotherapy and TKI combination for treatment of advanced/recurrent EC
Dr. Jung-Yun Lee
- Evolution of ICI combinations: ICI + chemotherapy for treatment of primary advanced/recurrent EC
Dr. Mansoor Raza Mirza
- Expansion of ICI: investigating combination with PARPi or TKI and beyond for treatment of primary advanced/recurrent EC
Dr. David SP Tan
- Panel discussion, Q&A from audience and concluding remarks
All



EC, endometrial cancer; ICI, immune checkpoint inhibitor; PARPi, poly (ADP-ribose) polymerase inhibitor; TKI, tyrosine kinase inhibitor.
This material was developed in compliance with the KRPIA/IFMA code.
This session is not included in main Congress CME/CPD credit.
©2023 GSK group of companies or its licensors. All rights reserved.
NKXGBL-DST-18ND-230007 October 2023

Sponsored by



IGCS 2023

Karyopharm
Therapeutics

An Industry Supported Symposium at the IGCS 2023 Annual Global Meeting
developed by Karyopharm in partnership with The GOG Foundation, Inc.

THE EVOLVING LANDSCAPE IN MOLECULAR-DRIVEN INVESTIGATIONAL THERAPIES FOR ADVANCED ENDOMETRIAL CANCER

This session is not included in the main event CME/CPD credit.

Agenda

Welcome & Introduction, Bradley J. Monk, MD & All Faculty

Impact of Endometrial Cancer Molecular Profiling on Emerging Treatment Landscape, Bradley J. Monk, MD

Considerations for Maintenance Treatment in Advanced Endometrial Cancer, Bradley J. Monk, MD, & All Faculty

Latest Molecular-Driven Clinical Trial Data in Front-Line Advanced Endometrial Cancer, Domenica Lorusso, MD, PhD, & All Faculty

Future Perspectives on Personalized Medicine for Endometrial Cancer, Ritu Salani, MD, MS, & All Faculty

Closing Remarks, Bradley J. Monk, MD

Bradley J. Monk, MD
US Cancer Associates

Domenica Lorusso, MD, PhD
University of Rome & Fondazione
Policlinica Gemelli IRCCS

Ritu Salani, MD, MS
UCLA Medical Center

MONDAY
NOVEMBER 6, 2023
Available Online

In Person Live Viewing
7:15 - 8:15 AM KST
Grand Ballroom 101-102

JOIN US TODAY <

This presentation is for scientific and educational purposes only, and does not directly or indirectly promote or seek to promote Karyopharm's products, or any other drugs.

MED-XUS-PIPE-2300014

An Industry Supported Symposium by Seagen at the IGCS 2023 Annual Global Meeting



Join the Conversation: Incorporating Breakthrough Cervical Cancer Data into Practice

Agenda

12:40 - 12:50: Keiichi Fujiwara, MD, PhD
Welcome & Introduction

12:50 - 13:10: Domenica Lorusso, MD & Keiichi Fujiwara, MD, PhD
Decoding the Latest Developments in Early Stage and First-Line Recurrent Cervical Cancer

13:10 - 13:30: Leslie Randall, MD & Ana Oaknin, MD
The Changing Landscape of Second-Line Therapies for Recurrent Cervical Cancer

13:30 - 13:50: Brian Slomovitz, MD
Have New Substances Changed How Patients are or will be Treated? Real-World Experiences

13:50 - 14:05: All Faculty
 Fireside Chat: Audience and Panel Facilitated Discussion

14:05 - 14:10: Keiichi Fujiwara, MD, PhD
Closing Remarks

JOIN US NOW



Keiichi Fujiwara, MD, PhD
Saitama Medical University International
Medical Center



Domenica Lorusso, MD, PhD
Fondazione Policlinica Gemelli IRCCS



Ana Oaknin, MD, PhD
Vall d'Hebron University Hospital (VH)UMH



Leslie Randall, MD
Massey Cancer Center
Virginia Commonwealth University



Brian Slomovitz, MD
Mount Sinai Medical Center

This session is not included in the main event CME/CPD credit.

Sunday
5 November 2023

12:40 - 14:10 KIST

COEX, Grand Ballroom 103
First Floor, 1F North



SEAGEN and its logos are trademarks of Seagen Inc., registered in the European Union and elsewhere. ©2023 Seagen Inc., USA. All rights reserved.
Date of preparation: September 2023 | Merken Number ASP/VW/2023/0006

PHILANTHROPY

MOVE 4 HER CAMPAIGN

Discover the power of unity as Move4Her brings together patients, survivors, caregivers, healthcare professionals, and organizations, encouraging everyone to stay active and motivated to reach their fundraising goals through the end of 2023.



All it takes is a commitment to FIVE minutes of daily movement!
Join the movement as an individual fundraiser, donate to support a friend or family member, start your own fundraising team, or host your own unique

fundraising event. No matter your approach, we are here to support you every step of the way on your fundraising journey.

[Click here](#) to Register now to become a Move4Her Fundraiser and start raising funds as an individual or as part of a Team.

NEW HORIZONS GYNECOLOGIC CANCER RESEARCH FUND



The New Horizons Gynecologic Cancer Research Fund is the philanthropic arm for The GOG Foundation, Inc. Donations allow the GOG to enrich efforts to develop and deliver essential research tools needed to further clinical trial development and translational research programs.

Donations from individuals, corporations, and foundations directly fund the GOG educational and research initiatives. Together, we collaborate with industry to find new treatments, and more effective prevention while promoting excellence in scientific research in the field of gynecologic malignancies.

Each donation received will go directly to provide:

- Much needed resources to effectively work towards the prevention and treatment of gynecologic malignancies
- Accessible research funding
- Ability to mentor New Investigators through fellowship awards
- Opportunity to raise public awareness through education and research
- Translational medicine initiatives across the disease committees

Click the Support Our Mission button below to make a donation today!

[Support Our Mission](#)

HOW CAN WE HELP?

The GOG Partners Connection Quarterly Newsletter is produced by the GOG Foundation Communications Committee.

Please contact us at info@gog.org with any questions or suggestions regarding future content.

[CONTACT US](#)

LET'S GET SOCIAL



[Unsubscribe cgaloppo@gog.org](#)

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by Imoeller@gog.org powered by



Try email marketing for free today!
